Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Dimitri E. Grigoriadis sold 30,000 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $74.58, for a total value of $2,237,400.00. Following the sale, the insider now owns 77,691 shares of the company’s stock, valued at $5,794,194.78. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Neurocrine Biosciences, Inc. (NBIX) traded up $0.04 during midday trading on Monday, reaching $75.46. The company had a trading volume of 768,500 shares, compared to its average volume of 1,130,864. Neurocrine Biosciences, Inc. has a fifty-two week low of $37.35 and a fifty-two week high of $75.98. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same quarter last year, the company earned ($0.43) earnings per share. equities research analysts predict that Neurocrine Biosciences, Inc. will post -1.74 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Dimitri E. Grigoriadis Sells 30,000 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock” was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.themarketsdaily.com/2017/11/13/dimitri-e-grigoriadis-sells-30000-shares-of-neurocrine-biosciences-inc-nbix-stock.html.
NBIX has been the subject of several research reports. Robert W. Baird reiterated an “outperform” rating and set a $66.00 price target on shares of Neurocrine Biosciences in a report on Thursday, September 21st. Jefferies Group LLC restated a “buy” rating and issued a $69.00 target price (up from $66.00) on shares of Neurocrine Biosciences in a report on Tuesday, October 3rd. Leerink Swann restated an “outperform” rating and issued a $83.00 target price (up from $72.00) on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Cowen and Company restated an “outperform” rating and issued a $65.00 target price (up from $60.00) on shares of Neurocrine Biosciences in a report on Wednesday, August 9th. Finally, Barclays PLC boosted their target price on Neurocrine Biosciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, November 2nd. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $78.88.
Several institutional investors have recently made changes to their positions in NBIX. First Trust Advisors LP grew its holdings in shares of Neurocrine Biosciences by 29.0% during the third quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock worth $47,963,000 after buying an additional 176,136 shares in the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of Neurocrine Biosciences by 49.7% during the second quarter. Canada Pension Plan Investment Board now owns 24,700 shares of the company’s stock worth $1,136,000 after buying an additional 8,200 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Neurocrine Biosciences by 14,216.0% during the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock worth $217,884,000 after buying an additional 4,996,784 shares in the last quarter. Artisan Partners Limited Partnership bought a new position in shares of Neurocrine Biosciences during the second quarter worth about $15,981,000. Finally, Davidson Kempner Capital Management LP bought a new position in shares of Neurocrine Biosciences during the second quarter worth about $3,639,000.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.